Abstract
The 30 years of the human immunodeficiency virus (HIV) epidemic have been marked by many triumphs. Today, thanks to life-saving anti-retroviral medications, patients are living longer than ever. However, despite scientific advances in the field of HIV treatment, HIV prevention has had less success. Despite efforts on several fronts, the number of new HIV diagnoses each year in the United States is unchanged. In this review, we will give a brief overview of the ups and downs of the field of HIV prevention, focusing on pre-exposure prophylaxis (PrEP). CAPRISA 004, iPrEx, FEMPREP, the VOICE trial and HPTN 052, among other prevention trials, are discussed. The CAPRISA 004 and iPrEx studies suggest optimism regarding the use of PrEP for those at risk for HIV infection, but the recent early termination of FEM-PREP and of one arm of VOICE has led to tempered enthusiasm. Many questions remain: Who should get PrEP? How long is it safe to take PrEP? What role will adherence play, and will there be problems with acquired resistance to the drugs with larger numbers using it daily? What is the best method of administering PrEP? Pre-exposure prophylaxis alone is unlikely to be the magic bullet- instead, this strategy will likely need to be part of a broader test-and-treat effort, ongoing education, treatment of sexually transmitted infections, and condom use.
Keywords: HIV infection, pre-exposure prophylaxis, HIV prevention, microbicides, test-and-treat, HIV transmission, HIV prophylaxis, risk-compensation
Current HIV Research
Title:Pre-Exposure Prophylaxis - One More Tool for HIV Prevention
Volume: 10 Issue: 2
Author(s): Anna K. Person and Charles B. Hicks
Affiliation:
Keywords: HIV infection, pre-exposure prophylaxis, HIV prevention, microbicides, test-and-treat, HIV transmission, HIV prophylaxis, risk-compensation
Abstract: The 30 years of the human immunodeficiency virus (HIV) epidemic have been marked by many triumphs. Today, thanks to life-saving anti-retroviral medications, patients are living longer than ever. However, despite scientific advances in the field of HIV treatment, HIV prevention has had less success. Despite efforts on several fronts, the number of new HIV diagnoses each year in the United States is unchanged. In this review, we will give a brief overview of the ups and downs of the field of HIV prevention, focusing on pre-exposure prophylaxis (PrEP). CAPRISA 004, iPrEx, FEMPREP, the VOICE trial and HPTN 052, among other prevention trials, are discussed. The CAPRISA 004 and iPrEx studies suggest optimism regarding the use of PrEP for those at risk for HIV infection, but the recent early termination of FEM-PREP and of one arm of VOICE has led to tempered enthusiasm. Many questions remain: Who should get PrEP? How long is it safe to take PrEP? What role will adherence play, and will there be problems with acquired resistance to the drugs with larger numbers using it daily? What is the best method of administering PrEP? Pre-exposure prophylaxis alone is unlikely to be the magic bullet- instead, this strategy will likely need to be part of a broader test-and-treat effort, ongoing education, treatment of sexually transmitted infections, and condom use.
Export Options
About this article
Cite this article as:
K. Person Anna and B. Hicks Charles, Pre-Exposure Prophylaxis - One More Tool for HIV Prevention, Current HIV Research 2012; 10 (2) . https://dx.doi.org/10.2174/157016212799937254
DOI https://dx.doi.org/10.2174/157016212799937254 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
HIV vaccine development
The development of a safe and effective vaccine that impedes HIV-1 transmission and/or limits the severity of infection remains a public health priority. The HIV-1/AIDS pandemic continues to have a disproportionate impact on vulnerable and under-served communities in the USA and globally. In the USA, minority communities that have relatively ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neuro-psychopharmacogenetics and Neurological Antecedents of Posttraumatic Stress Disorder: Unlocking the Mysteries of Resilience and Vulnerability
Current Neuropharmacology HIV-1 Matrix Protein p17 and its Receptors
Current Drug Targets Medicinal Chemistry Discoveries among 1,3,5-Triazines: Recent Advances (2000-2013) as Antimicrobial, Anti-TB, Anti-HIV and Antimalarials
Mini-Reviews in Medicinal Chemistry Vitamin D Intervention Trials in Critical Illness
Inflammation & Allergy - Drug Targets (Discontinued) Rheumatic Manifestations in Malignancy
Current Rheumatology Reviews Biology of gama delta T Cells in Tuberculosis and Malaria
Current Molecular Medicine Comparative Proteome Profiles of Methicillin-Resistant <i>Staphylococcus aureus</i> in Response to Vanillic Acid and 2-Hydroxycinnamic Acid
Current Proteomics Inhibitory MHC Class I Receptors on Myeloid Cells
Current Immunology Reviews (Discontinued) Do You See What I See: Recognition of Protozoan Parasites by Toll-Like Receptors
Current Immunology Reviews (Discontinued) Editorial (Thematic Issue: Role of Data and Methods in Chemoinformatics for Virtual Screening)
Combinatorial Chemistry & High Throughput Screening Noscapine-loaded PLA Nanoparticles: Systematic Study of Effect of Formulation and Process Variables on Particle Size, Drug Loading and Entrapment Efficiency
Pharmaceutical Nanotechnology Mass Spectrometry in the Elucidation of the Glycoproteome of Bacterial Pathogens
Current Proteomics Small Molecule Hydrazide Agents to Inhibit Growth and Proliferation of Mycobacterium Tuberculosis
Medicinal Chemistry Effect of Antitubercular Therapy on Endometrial Function in Infertile Women with Female Genital Tuberculosis
Infectious Disorders - Drug Targets Recent Patents on DNA Sequences and Diagnostic Methods for the Identification and Strain Differentiation of Mycobacterium Tuberculosis
Recent Patents on DNA & Gene Sequences Design, Synthesis and In vitro Biological Activity of Some New 1,3- thiazolidine-4-one Derivatives as Chemotherapeutic Agents using Virtual Screening Strategies
Current Computer-Aided Drug Design Evaluation of In Vivo and In Vitro Antimicrobial Activities of a Selective Serotonin Reuptake Inhibitor Sertraline Hydrochloride
Anti-Infective Agents Stereochemistry at the Forefront in the Design and Discovery of Novel Anti-tuberculosis Agents
Current Topics in Medicinal Chemistry One-Step Synthesis of 1H-1,2,3-Triazol-1-Ylmethyl-2,3-Dihydronaphtho[1,2-b]furan- 4,5-Diones
Current Organic Synthesis The Epidemiology and Health Effects of Tobacco Use
Current Pediatric Reviews